首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

細胞和基因治療市場規模、佔有率和成長分析（按治療方法、治療領域、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1899701

細胞和基因治療市場規模、佔有率和成長分析（按治療方法、治療領域、最終用戶和地區分類）—2026-2033年產業預測

Cell and Gene Therapy Market Size, Share, and Growth Analysis, By Therapy Type (Cell Therapy, Gene Therapy), By Therapeutic Class (Cardiovascular Disease, Rare Diseases), By End Users, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 194 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球細胞和基因治療市場規模預計在 2024 年達到 294.4 億美元，從 2025 年的 348.8 億美元成長到 2033 年的 1356.2 億美元，在預測期（2026-2033 年）內複合年成長率為 18.5%。

全球細胞和基因治療市場的成長主要受慢性疾病（例如癌症和罕見遺傳疾病）的日益增多所驅動，這些疾病難以透過傳統治療方法有效治療。這項持續存在的醫療挑戰促使醫療專業人員和製藥公司尋求能夠提供標靶、個人化治療的創新治療方法。篩檢技術的進步和人口老化導致確診患者數量不斷增加，進一步推動了對這些治療方法的需求，從而增加了投資和臨床試驗。生物技術領域的突破性進展，特別是基因編輯技術（例如 CRISPR-Cas9），正在提高治療的精準性和患者安全性，並促進監管部門的核准。這些進步不僅加速了研發進程，也吸引了更多投資，並擴大了市場上新型治療方法方案的數量。

全球細胞和基因治療市場按治療方法類型、治療疾病、最終用戶和地區進行細分。依治療方法類型分類，市場分為細胞治療和基因治療兩大類。依治療疾病分類，市場分為心血管疾病、癌症、遺傳性疾病、罕見疾病、腫瘤、血液疾病、眼科疾病、感染疾病、神經系統疾病及其他疾病。依最終用戶分類，市場分為醫院、癌症治療中心等機構。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球細胞和基因治療市場促進因素

遺傳性疾病和罕見疾病的日益普遍正顯著地推動細胞和基因治療市場的發展。這些先進治療方法為曾經被認為無法治癒的疾病提供了根治性方案，引起了患者和醫療服務提供者的極大關注。不斷成長的患者需求和診斷技術的進步推動了對創新和標靶治療方法的需求。這一趨勢正在促進突破性治療方法的研發和投資，以應對複雜的健康挑戰，從而為全球細胞和基因療法市場創造了良好的發展環境。因此，該市場正經歷著巨大的成長和擴張機會。

限制全球細胞和基因治療市場的因素

全球細胞和基因治療市場面臨許多限制因素，例如開發這些治療方法需要大量的臨床前研究、複雜的臨床試驗以及嚴格的監管核准流程。產品上市週期過長不僅會延緩其上市時間，還會增加研發成本。對於中小企業而言，這項挑戰尤其突出，因為它們往往難以應對漫長的投資週期。因此，創新可能會受到抑制，最終影響新治療方法進入全球市場的速度，並限制患者治療方案的進展。

全球細胞和基因治療市場趨勢

全球細胞和基因治療市場正經歷一場變革，而這主要得益於個人化醫療的興起。個人化醫療能夠根據患者獨特的基因譜量身定做治療方案，從而提高療效並最大限度地減少有害副作用，尤其適用於治療罕見疾病和複雜疾病。隨著醫療保健越來越注重以患者為中心的解決方案，利用基因資訊進行創新治療方法的需求也隨之飆升。這一趨勢不僅加速了市場成長，也促進了研究人員、醫療服務提供者和生技公司之間的合作，最終將為全球帶來更有效的治療方法和更好的患者療效。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Novartis（Switzerland）
Gilead Sciences（USA）
Bristol Myers Squibb（USA）
bluebird bio（USA）
Kite Pharma（USA）
Sangamo Therapeutics（USA）
Moderna（USA）
Editas Medicine（USA）
Cellectis（France）
Orchard Therapeutics（UK）
UniQure（Netherlands）
Regenxbio（USA）
Spark Therapeutics（USA）
Fosun Pharma（China）
MeiraGTx（UK）

結論與建議

簡介目錄

Product Code: SQMIG35D2325

Global Cell & Gene Therapy Market size was valued at USD 29.44 Billion in 2024 and is poised to grow from USD 34.88 Billion in 2025 to USD 135.62 Billion by 2033, growing at a CAGR of 18.5% during the forecast period (2026-2033).

The global cell and gene therapy market is significantly propelled by the rising prevalence of chronic diseases, including cancer and rare genetic disorders, which often elude effective treatment from traditional modalities. This ongoing medical challenge drives healthcare professionals and pharmaceutical entities to pursue innovative therapies that provide targeted and personalized solutions. The growing pool of diagnosed patients, aided by advancements in screening and an aging demographic, further fuels demand for these therapies, resulting in increased investment and clinical trials. Breakthroughs in biotechnology, particularly with gene editing technologies like CRISPR-Cas9, enhance therapeutic precision and patient safety, facilitating regulatory approvals. These advancements not only accelerate research and development but also attract further investments, broadening the array of novel treatments in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell & Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell & Gene Therapy Market Segments Analysis

The global cell and gene therapy market is segmented based on therapy type, therapeutic class, end-users, and region. In terms of therapy type, the market is bifurcated into cell therapy and gene therapy. Based on therapeutic class, the market is segmented into cardiovascular disease, cancer, genetic disorder, rare diseases, oncology, hematology, ophthalmology, infectious disease, neurological disorders, and others. Based on end-users, the market is trifurcated into hospitals, cancer care centers, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.

Driver of the Global Cell & Gene Therapy Market

The increasing prevalence of genetic disorders and rare diseases significantly propels the cell and gene therapy market. These advanced therapies provide curative solutions for ailments once thought to be untreatable, attracting considerable interest from both patients and healthcare providers. With heightened patient demand and advancements in diagnostic technologies, there is an escalating necessity for innovative and targeted treatment options. This trend fosters a robust environment for the global cell and gene therapy market, encouraging further development and investment in groundbreaking therapies aimed at tackling complex health challenges. As a result, the market is experiencing substantial growth and expansion opportunities.

Restraints in the Global Cell & Gene Therapy Market

The Global Cell and Gene Therapy market faces significant constraints due to the extensive preclinical research, intricate clinical trials, and stringent regulatory approval processes required for developing these therapies. The lengthy timeline for bringing products to market not only delays their availability but also escalates research and development costs. This challenge is particularly pronounced for smaller companies, which often find it difficult to manage prolonged investment cycles. As a result, innovation may be hindered, ultimately affecting the rate of new therapies entering the global market and limiting advancements in treatment options for patients.

Market Trends of the Global Cell & Gene Therapy Market

The global cell and gene therapy market is witnessing a transformative trend driven by the emergence of personalized medicine, which tailors treatments to the unique genetic profiles of patients. This individualized approach enhances therapeutic efficacy and minimizes adverse side effects, making it particularly beneficial for addressing rare and complex diseases. As healthcare becomes increasingly focused on patient-centric solutions, the demand for innovative therapies that harness genetic insights is surging. This trend not only accelerates market growth but also fosters a collaborative environment among researchers, healthcare providers, and biotechnology firms, ultimately leading to more effective treatments and better patient outcomes on a global scale.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Cell and Gene Therapy Market Size by Therapy Type & CAGR (2026-2033)

Market Overview
Cell Therapy
Gene Therapy

Global Cell and Gene Therapy Market Size by Modality & CAGR (2026-2033)

Market Overview
In Vivo
Ex Vivo

Global Cell and Gene Therapy Market Size by Indication & CAGR (2026-2033)

Market Overview
Oncology
Cardiovascular Diseases
Neurological Disorders
Musculoskeletal Disorders
Ophthalmic Disorders
Metabolic & Genetic Disorders
Infectious Diseases
Others

Global Cell and Gene Therapy Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals & Clinics
Academic & Research Institutes
Biopharmaceutical & Biotechnology Companies
Cell Therapy Centers
Others

Global Cell and Gene Therapy Market Size & CAGR (2026-2033)

North America (Therapy Type, Modality, Indication, End User)
- US
- Canada
Europe (Therapy Type, Modality, Indication, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Therapy Type, Modality, Indication, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Therapy Type, Modality, Indication, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Therapy Type, Modality, Indication, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bluebird bio (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kite Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Editas Medicine (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellectis (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orchard Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UniQure (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regenxbio (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Spark Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fosun Pharma (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MeiraGTx (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments